Abstract

A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants

English, M. MacLennan, J. M. Bowen-Morris, J. M. Deeks, J. Boardman, M. Brown, K. Smith, S. Buttery, J. Clarke, J. Quataert, S. Lockhart, S. Moxon, E. R.
Vaccine. 2000; 191232-8

Permanent descriptor

https://doi.org/10.1016/s0264-410x(00)00241-3

A double-blind, randomised, controlled trial was conducted in 248 British infants to assess the immunogenicity and tolerability of three doses of a meningococcal group C/CRM (197) conjugate vaccine (Lederle Laboratories, USA) given at 2, 3 and 4 months. Control children received three doses of Hepatitis B vaccine (Engerix B(R); SmithKline Beecham). At 5 months of age, 100% of children receiving the conjugate vaccine had specific immunoglobulin G concentrations >2.0 microg/ml (n=116) compared with only 4% of control children (n=121). Those receiving the conjugate also had 2.5- and 1.6-fold higher geometric mean concentrations of PRP and diphtheria antibodies, respectively. The vaccine was well tolerated.